ALTERATION OF THE CELL CYCLE IN VIVO, AND PARTICULARLY FOR INDUCING APOPTOSIS OF TUMOR CELLS

Abstract: A first substance (such as the peptide aldehydes LLnL and LVP) inhibits the function of intracellular proteasome. A second substance (such as ranpirnase) inhibits intracellular protein synthesis or increases intracellular expression of a cyclin-dependent kinase (CDK) inhibitor. Both substances are administered in such a manner that the effects thereof are coincident. The cell cycle of affected tumor cells is therefore arrested and the cells die of apoptosis.

Description: ALTERATION OF THE CELL CYCLE IN VIVO, AND PARTICULARLY FOR INDUCING APOPTOSIS OF TUMOR CELLS Background of the Invention The invention relates to cell biology, and more particularly relates to apoptosis . In its most immediate sense, the invention relates to methods for inducing apoptosis in tumor cells in vivo . It has long been known that cancerous tumors are created by the unregulated growth of undifferentiated tumor cells. Hence, scientists have long sought therapies that would prevent tumor cells from growing. To do this, scientists have attempted to disrupt the cell cycle of proliferating HL-60 tumor cells by treating them with N-acetyl-leucinyl-leucinyl-norleucinal (LLnL) , a peptide aldehyde known to inhibit the function of proteasome. This arrested the HL-60 cells in the Gl phase of the cell cycle, and in turn prevented them from entering the S phase. When such cells were thus prevented from progressing to subsequent stages of the cell cycle, they died (which is a phenomenon known as programmed cell death, or apoptosis) . However, such experiments focus narrowly upon only one aspect of the cell cycle, namely, inhibiting the function of proteasome (which has been shown to be necessary to normal cell-cycle progression) . In fact, progression of cells along the cell cycle comes about as a result of a most complex balancing mechanism. At any given point in the cell cycle, the cells are subjected to biological mechanisms that tend to progress them along the cell cycle as well as biological mechanisms that tend to retain them in whatever phase of the cell cycle they are presently in. Whether or not a cell actually progresses from e.g. the Gl phase to the S phase or from the S phase to the G2 phase or from G2 to mitosis (M phase) is determined by a balance of biological forces acting on that cell; if the positive influence of e.g. cyclins (which act to stimulate progression in the cell cycle) predominates over the negative influence of e.g. kinase inhibitors (which act to arrest cells in their existing cell cycle phase) , then the cells may enter or leave the S phase; if not, they may not. The invention proceeds from the realization that existing approaches to promoting apoptosis of tumor cells do not utilize such positive and negative influences concurrently. As a result, such approaches are not as effective as they might otherwise be. In accordance with the invention, therapeutically effective doses of two substances are administered in vivo in such a manner that their effects are concurrent. The first substance arrests the cells in a particular phase of the cell cycle, and the second substance prevents the cells from progressing beyond that phase. In this way, the above- referenced balancing mechanism is used to most effectively prevent tumor cells from growing and to thereby induce apoptosis . In accordance with preferred embodiments, the first substance inhibits intracellular proteasome function, or inhibits activation of NFKB, or both. (If the function of proteasome within the cell is inhibited, activation of NFKB within the cell will likewise be inhibited. This is because NFKB is a heterodimer that has as one of its components a protein known as p50. Normally, the p50 protein is produced by proteolytic processing of its precursor protein pl05, which processing is a function of proteasome. When proteasome function is inhibited, the p50 protein is not produced, and instead of producing an active NFKB heterodimer from p50 protein and another protein known as p65 protein, an inactive heterodimer is produced from pl05 protein and p65 protein. Additionally, when proteasome function is inhibited, this prevents proteolytic degradation of the IKB protein, which inhibits the function of NFKB by complexing with it and preventing it from entering the nucleus of the cell. In other words, inhibition of proteasome function also inhibits the function of NFKB by reducing the extent to which an inhibitor of NFKB is destroyed.) Two peptide aldehydes, namely LLnL and N- acetyl-leucinyl-valinyl-phenylalaninal (LVP) , are suitable for this. The phase in which inhibition of intracellular proteasome function arrests the cell cycle may vary. As stated above, in HL-60 cells the arrest occurs in the Gl phase, but in DU-145 human prostate carcinoma cells, the arrest occurs in the G2 phase. In accordance with the preferred embodiment, the second substance inhibits intracellular protein synthesis, or increases intracellular expression of a cyclin-dependent kinase (CDK) inhibitor such as p27KIPl. Ranpirnase is suitable for this. (Ranpirnase is the USAN-approved generic name of the pharmaceutical that is described and claimed in U.S. Patent No. 5,559,212 and that is presently known by the registered trademark ONCONASE . ) The above-referenced concurrent effects can be achieved by administering both substances separately (as by injections, oral administrations, or both) as long as the substances are administered in such a manner as to cause their effects to be concurrent. It is believed that the above-referenced concurrent effects can also be achieved by administering both substances simultaneously (as in a mixture or other form containing both) . Detailed Description of Preferred Embodiments In vitro experiments were conducted using five drugs on three cell lines. The drugs were ranpirnase, doxorubicin, LLnL, LVP, and N-acetyl-leucinyl-leucinyl-methioninal (LLM) , and the cell lines were DU-145 human prostate carcinoma, A- 549 human lung carcinoma, and MDA-MB-231 human breast carcinoma. In vivo experiments were conducted using ranpirnase, doxorubicin and LLnL and the MDA-MB-231 human breast carcinoma cell line in nude mice. In vitro Materials and Methods: Cell Lines The DU-145, A-549, and MDA-MB-231 cell lines were purchased from the American Type Culture Collection. The A-549 cells were grown as previously described in Cell Tissue Kinet 23:237, 1990. The DU-145 cell line was maintained in Eagle's Minimum Essential Medium supplemented with 10% fetal bovine serum (FBS) , 1% glutamine, and 1% Pen- Strep-Fungizone . The cell number of DU-145 cells used in the MTT assay was 10,000 cells/well. The MDA-MB-231 cell line was maintained in Liebovitz's L-15 medium supplemented with 10% FBS, 1% glutamine, and 1% Pen-Strep-Fungizone . The cell number of the MDA-MB-231 cells used in the MTT assay was 10,000 cells/well. All agents were obtained from JRH Bioscience, Lenexa, KS . The determination of cell number, description of the MTT colorimetric assay, and statistical analyses (including assessments of synergistic interactions) were as previously described in Cell Tissue Kinet 23:237, 1990 and Adv Cancer Res 35:269, 1981. In vitro Drugs Ranpirnase was dissolved as previously described in Cell Tissue Kinet 23:237, 1990. The LLnL, LLM, and N- acetyl-leucinyl-valinyl-phenylalaninal (LVP) were purchased from Sigma Corporation, St Louis, MO. All three were dissolved in 100% ethanol to produce a 1 mM stock solution. The stock solution was diluted in growth medium of the cell line being tested to produce the solution that was added to the plates containing the cells for the MTT assay. In vitro Experimental Results Ranpirnase and LLnL interact synergistically against the DU-145, A-549, and MDA-MB-231 cell lines (Tables 1 and 2) . In the A-549 and DU-145 cell lines, the anti-tumor activity of ranpirnase was also augmented by LVP but not by LLM (Table 3) . The activity of ranpirnase against the MDA- MB-231 cell line was only minimally affected by the additional treatment with 25 μM LLM (the mean ED 50 value was decreased by approximately two-fold (Table 3) . These findings are consistent with a previously published report in Proc Natl Acad Sci USA 94:855-860, 1997 that LLM peptide does not significantly inhibit the activity of proteasome. In MDA-MB-231 cells, ranpirnase interacts synergistically with LLnL at the final concentrations of ranpirnase in the range of 0.1 to 10.0 μg/mL and of LLnL in the range of 5 to 25 μM, and particularly at the LLnL concentrations in the range between 10 and 25 μM. The mean ED S0 value for ranpirnase decreased from 1.434 μg/mL (ranpirnase alone) to 0.037, 0.022, and 0.001 μg/mL for ranpirnase in combination with LLnL at, respectively, the 10, 15, and 25 μM concentrations of LLnL (Table 2). In addition, the combinations of ranpirnase with 0.1 μg/mL (approximately 0.17 μM) doxorubicin with and without 15 μM LLnL were tested (Table 4) . The mean ED 50 value for ranpirnase when used in combination with doxorubicin was decreased 2.2 -fold as compared with the mean ED 50 value for ranpirnase alone. In these conditions, the addition of doxorubicin did not significantly decrease cell growth or cell viability when the triple combination of ranpirnase plus doxorubicin plus LLnL was compared with ranpirnase plus LLnL without doxorubicin (Table 4) . In A-549 cells, the combination of ranpirnase and LLnL was synergistic at higher concentrations (15 to 35) μM of LLnL (Table 1) . Lower concentrations of 10 μM of LLnL with lower concentrations (0.1 to 1.0 μg/mL) of ranpirnase were not synergistic, but the effect of the combination was greater than the effect of ranpirnase alone (Table 2) . The mean ED 50 value for ranpirnase decreased from 3.944 μg/mL (ranpirnase alone) to 1.356, 0.640, 0.060, and less than 0.001 μg/mL for the combinations of ranpirnase with LLnL at, respectively, LLnL concentrations of 10, 15, 25, and 35 μM (Table 2) . In DU-145 cells, ranpirnase was synergistic with LLnL SUBSTTTUTE SHEET (RULE 26 across all the concentrations of ranpirnase and the 10 to 25 μM concentrations of LLnL (Table 1) . The respective ED 50 values for ranpirnase alone and for ranpirnase combined with 10, 15, and 25 μM LLnL, were: 42.276, 1.231, 0.001, and < 0.001 μg/mL (Table 2). To test whether the observed anti- tumor activity of the combination resulted from apoptosis, an excess (at the final concentrations of 50 μM) of Ac-DEVD- cho (N-acetyl-L-aspartyl-L-glutamyl-L-valinyl-L-aspartal) was added to overcome a recognized difficulty of its ability to penetrate plasma membranes. (Ac-DEVD-cho was chosen because it is a known inhibitor of caspases . Caspases are cysteine-proteases that are involved in apoptotic cell death.) Ac-DEVD-cho increased approximately 2- to 3-fold the viability of cells treated with a combination of ranpirnase and 25 μM LLnL. Under identical conditions, but without ranpirnase, the combination of LLnL and Ac-DEVD-cho increased viability of cells approximately 4-fold as compared with cells treated with LLnL alone (Table 5) . This suggests that at least part of the anti-tumor activity observed was a manifestation of apoptotic cell death. Newman-Keuls statistical analyses were performed to establish whether or not the observed differences between the anti-tumor activities of ranpirnase as a single agent and ranpirnase combined with the respective peptide inhibitors were significant (Table 6) . As shown, the anti- tumor activity of ranpirnase combined with LLnL proteasome inhibitor was significantly greater than that of each of the agents used as a single agent in all tumor cell lines tested. There was no significant effect of the 25 μM LLM peptide on the growth and viability of the MDA-MB-231 cells when compared with untreated controls, and there was no significant difference between the activity of the combination of ranpirnase and 25 μM LLM peptide and the activity of ranpirnase alone (Table 6) . In flow cytometry studies of DU-145 cells, apoptosis appeared to be concurrent with G2 phase arrest of the cell cycle . In vivo Experimental Results In vivo experiments (see Table 7) were carried out on nude mice bearing MDA-MB-231 tumors to compare the activities of ranpirnase and LLnL as single agents with the activity of ranpirnase and LLnL together. The dosages of ranpirnase and LLnL were 2.5 mg and 5 mg per kilogram of mouse body weight, respectively. In the above-referenced experiments, ranpirnase and LLnL were individually administered in vivo intraperitoneally by two immediately successive injections on a twice-weekly schedule for three weeks. Other forms of administration (e.g. using other dose forms, with or without other agents to enhance delivery to an intended location within the body) may also be possible as long as the effects thereof are coincident. Furthermore, although it is presently expected that it will be most advantageous to administer the invention in a single dose form (with or without the addition of one or more other agents to enhance delivery to an intended location within the body) this has not yet been experimentally verified. Although at least one preferred embodiment of the invention has been described above, this description is not limiting and is only exemplary. The scope of the invention is defined only by the claims, which follow: TABLE INTERACTION INDEX RAN RAN + RAN + RAN + RAN + RAN + 5 μM LLnL 10 μM LLnL 15 μM LLnL 25 μM LLnL 35 μM LLnL A-549 Cells 0.1 1.145 (A) a 0.963 (S) b 0.816 (S) 0.801 (S) c (0 1.0 1.001 (A) 0.819 (S) 0.672 (S) 0.657 (S) CD 10.0 0.344 (S) 0.162 (S) 0.015 (S) 0.001 (S) DU-145 Cells C 0.1 0.963 (S) 0.935 (S) 0.934 (S) 1.0 0.671 (S) 0.643 (S) 0.642 (S) 10.0 0.313 (S) 0.285 (S) 0.284 (S) - M MDDAA--;MB-231 Cells t 0.1 0.691 (S) 0.469 (S) 0.468 (S) 0.444 (S) 1.0 0.660 (S) 0.438 (S) 0.427 (S) 0.413 (S) 10.0 0.248 (S) 0.026 (S) 0.015 (S) 0.001 (S) Interaction index (I.I = 1.000 indicates no interaction > 1.000 indicates antagonism (A) < 1.000 indicates synergism (S) TABLE 2 MEAN % CELL VIABILITY AND ED 50 VALUES Group RAN→ 0.0 (μg/mL) 0.1 (μg/mL) 1.0 (μg/mL) 10.0 (μg/mL) ED 50 A-549 Cells RAN alone 100 (0.0)* 89.0 (1.0) 71.4 (4.4) 19 .0(0, .3) 3 , .944 RAN + LLnL 10 μM 86.4 (8.4) 74.2 (1.5) 65.6 (7.5) 18, .1(3, .7) 1, .356 RAN + LLnL 15 μM 81.3 (4.6) 65.7 (0.1) 62.5 (2.5) 12. .9(0. .0) 0, .640 RAN + LLnL 25 μM 53.8 (1.8) 44.9 (0.5) 30.5 (0.0) 4. .6(0. .9) 0. .060 CO c RAN + LLnL 35 μM 21.5 (0.9) 16.9(3.6) 8.2(0.0) 1. .0(0. .1) < 0. .001 CD CO DU-145 Cells RAN alone 100 (0.0) 96.3 (0.8) 94.9 (1.3) 40.8(0.3) 42.276 o RAN + LLnL 10 μM 85.6 (1.3) 74.9(6.6) 54.8 (5.8) 23.5 (2.2) 1.231 RAN + LLnL 15 μM 55.1 (4.5) 49.6 (4.6) 26.7 (0.8) 16.5 (0.6) 0.001 I RAN + LLnL 25 μM 10.4 (1.3) 13.5 (0.4) 5.9 (2.9) 4.8(1.2) < 0.001 MDA-MB-231 Cells > RAN alone 100 (0.0) 69.2 (12.9] 61.6 (2.7) 21.4 (4.5) 1.434 RAN + LLnL 5 μM 86.2 (2.2) 56.6(5.2) 51.8 (4.8) 16.9(9.6) 0.356 RAN + LLnL 10 μM 62.3 (0.6) 32.8 (5.9) 33.9(4.9) 4.9(6.6) 0.037 RAN + LLnL 15 μM 48.9 (4.8) 31.5(0.1) 21.9 (2.9) 7.3 (9.9) 0.022 RAN + LLnL 25 μM 22.6 (10.7) 21.9(9.8) 11.6 (6.6) 6.1 (8.0) 0.001 *Numbers in parentheses = standard deviations. RAN = Ranpirnase LLnL = -acetyl-leucinyl-leucinyl-norleucinal TABLE MEAN % CELL VIABILITY AND ED 50 VALUES COMPARISON OF TREATMENTS WITH LLnL AND LLM PEPTIDES Treatment RAN 0.0 (μg/mL) 0.1 (μg/mL) 1.0 (μg/mL) 10.0 (μg/mL) ED 50 A-549 Cells Control 100 ( o .0) * RAN alone 88 .6( 7.8) 82 .9(0.4) 31, .1(3 .1) 6, .838 RAN+LLnL 25 μM 67. .4( 9. .9) 59, .1(4.5) 50 .5(5.1) 15. .7 (2 , .7) 0, .322 RAN+LLM 25 μM 116. .9(10. .2) 97. .8(2.1) 87, .6(5.1) 33. .0 (4, .8) 9. .233 RAN+LVP 25 μM 25. .7 ( 0. .8) 20. .6(0.3) 17, .4(0.4) 10. .4(0. .4) < 0. .001 DU-145 Cells Control 100 (0.0) RAN alone 89.2 (3.4) 68.5 (3.9) 29.4 (1.4) 3.944 RAN+LLnL 25 μM 42, .0 (5. .0) 34.7 (0.6) 26.3 (1.1) 11.8 (1.5) 0.006 RAN+LLM 25 μM 99, .9 (4. .1) 79.1 (5.8) 67.9(1.0) 38.0 (0.4) 5.386 RAN+LVP 25 μM 42, .9(1. .5) 30.5 (0.5) 17.2 (2.4) 9.7 (0.4) 0.003 TABLE EFFECT OF CASPASE INHIBITOR ON DU-145 CELL VIABILITY MEAN % OF CONTROL AND ED 50 VALUES Group RAN —> 0.0 (μg/mL) 0.1 (μg/mL) 1.0 (μg/mL) 10.0 (μg/mL) ED 50 RAN alone 100 (0.0) 96.3 (0.8) 94.9 (1.3) 40.8 (0.3) 42.276 CO C CD CO RAN + DEVD 50 μM 104 (8.2) 99.5 (0.2) 89.5 (7.0) 41.2 (0.5) 13.610 RAN + LLnL 25 μM 10.4(1.3) 1 .5 (0.4) 5.9 (2.9) 4.8(1.2) < 0.001 H m 50 μM + 44.2 (0.9) 34.4 (0.2) 14.9 (0.5) 14.8 (0.4) 0.002 parentheses = standard deviations. o RAN = Ranpirnase LLnL = N-acetyl -leucinyl-leucinyl-norleucinal DEVD = Ac-DEVD-cho (.N-acetyl-L-aspartyl-L-glutamyl-L-valinyl-Laspartai; TABLE Newman-Keuls Analyses (p values) Comparison: RAN 0 (μg/mL) 0.1 (μg/mL) 1.0 (μg/mL) 10.0 (μg/mL) A-549 Cells LLnL 10 μM vs. Control 0.001 LLnL 15 μM vs. Control 0.001 LLnL 25 μM vs. Control 0.001 LLnL 35 μM vs. Control 0.001 RAN alone vs. RAN+10 μM LLnL 0.001 NS NS RAN alone vs RAN+15 μM LLnL 0.001 0.1 NS RAN alone vs RAN+25 μM LLnL 0.001 0.001 0.001 RAN alone vs RAN+35 μM LLnL 0.001 0.001 0.001 O RAN+15 μM vs RAN+25 μM LLnL 0.001 0.001 0.1 DU-145 Cells LLnL 10 μM vs Control 0. .001 o LLnL 15 μM vs Control 0. .001 LLnL 25 μM vs , Control 0. .001 RAN alone vs. RAN+10 μM LLnL 0.001 NS NS RAN alone vs. RAN+15 μM LLnL 0.001 0.1 NS RAN alone vs. RAN+25 μM LLnL 0.001 0.001 0.001 RAN+10 μM vs. RAN+15 μM LLnL 0.001 0.001 NS RAN+10 μM vs. RAN+25 μM LLnL 0.001 0.001 0.001 RAN+15 μM vs. RAN+25 μM LLnL 0.001 0.001 0.001 TABLE 6 (page 2) Comparison : RAN 0 (μg/mL) 0.1 (μg/mL) 1.0 (μg/mL) 10.0 (μg/mL) MDA-MB-231 Cells LLnL 5 μM vs . Control NS LLnL 10 μM vs. Control 0.001 LLnL 15 μM vs Control 0.001 LLnL 25 μM vs Control 0.001 LLM 25 μM vs. Control NS RAN alone vs. RAN+5 μM LLnL NS NS NS O RAN alone vs. RAN+10 μM LLnL 0.001 0.01 NS c CD RAN alone vs . RAN+15 μM LLnL 0.001 0.001 NS CO RAN alone vs. RAN+25 μM LLnL 0.001 0.001 NS RAN alone vs. RAN+25 μM LLM NS NS NS H c m RAN+5 μM vs RAN+15 μM LLnL 0.01 0.01 NS co x RAN+5 μM vs RAN+25 μM LLnL 0.001 0.001 NS RAN+10 μM vs. RAN+25 μM LLnL NS 0.1 NS π RAN = Ranpirnase o LLnL = N-acetyl -leucinyl-leucinyl-norleucinal LLM = N-acetyl-leucinyl-leucinyl-methioninal Table 7 Survival of Nude Mice with MDA-MB-231 Breast Cancer Ranpirnase Dosage: 50 μg/mouse, 2x/wk for 3 weeks LLnL Dosage: 100 μg/mouse, 2x/week for 3 weeks LLnL = N-acetyl-leucinyl-leucinyl-norleucinal

Claims: 1. A method altering the cell cycle of cells in a living patient, comprising the steps of arresting said cells in a predetermined phase of the cell cycle by administering a therapeutically active dose of a first substance, and concurrently preventing said cells from progressing beyond said predetermined phase of the cell cycle by administering a therapeutically active dose of a second substance. 2. A method for inducing apoptosis of tumor cells in vivo, comprising the steps of arresting said cells in a predetermined phase of the cell cycle by administering a therapeutically active dose of a first substance, and concurrently preventing said cells from progressing beyond said predetermined phase of the cell cycle by administering a therapeutically active dose of a second substance. 3. A method for altering the cell cycle of cells in a living patient, comprising the steps of: administering to the patient a therapeutically active dose of a first substance that inhibits intracellular proteasome function; and administering to the patient a therapeutically active dose of a second substance that acts to inhibit intracellular protein synthesis, said administering steps being carried out in such a manner that the effects thereof are concurrent. 4. The method of claim 3, wherein the first substance is a peptide. 5. The method of claim 4, wherein the first substance is a peptide aldehyde. 6. The method of claim 5, wherein the peptide aldehyde is N-acetyl-leucinyl-leucinyl-norleucinal (LLnL) . 7. The method of claim 5, wherein the peptide aldehyde is N-acetyl-leucinyl-valinyl-phenylalaninal (LVP) . 8. The method of claim 3, wherein the second substance is a ribonuclease (RNase) . 9. The method of claim 8, wherein the RNase is ranpirnase. 10. A method for altering the cell cycle of cells in a living patient, comprising the steps of: administering to the patient a therapeutically active dose of a first substance that inhibits intracellular activation of NFKB; and administering to the patient a therapeutically active dose of a second substance that acts to inhibit intracellular protein synthesis, said administering steps being carried out in such a manner that the effects thereof are concurrent. 11. The method of claim 10, wherein the first substance is a peptide. 12. The method of claim 11, wherein the first substance is a peptide aldehyde. 13. The method of claim 12, wherein the peptide aldehyde is JV-acetyl-leucinyl-leucinyl-norleucinal (LLnL) . 14. The method of claim 12, wherein the peptide aldehyde is N-acetyl-leucinyl-valinyl-phenylalaninal (LVP) . 15. The method of claim 10, wherein the second substance is a ribonuclease (RNase) . 16. The method of claim 15, wherein the RNase is ranpirnase. 17. A method for altering the cell cycle of cells in a living patient, comprising the steps of: administering to the patient a therapeutically active dose of a first substance that inhibits intracellular proteasome function; and administering to the patient a therapeutically active dose of a second substance that increases intracellular expression of a cyclin-dependent kinase (CDK) inhibitor, said administering steps being carried out in such a manner that the effects thereof are concurrent. 18. The method of claim 17, wherein the CDK inhibitor is p27KIPl. 19. The method of claim 18, wherein the first substance is a peptide. 20. The method of claim 18, wherein the first substance is a peptide aldehyde. 21. The method of claim 20, wherein the peptide aldehyde is N-acetyl-leucinyl-leucinyl-norleucinal (LLnL) . 22. The method of claim 20, wherein the peptide aldehyde is N-acetyl-leucinyl-valinyl-phenylalaninal (LVP) . 23. The method of claim 18, wherein the second substance is a ribonuclease (RNase) . 24. The method of claim 23, wherein the RNase is ranpirnase. 25. A method for inducing apoptosis of tumor cells in vivo, comprising the steps of arresting said cells in the G2 phase of the cell cycle by inhibiting intracellular proteasome function, and concurrently preventing said cells from progressing beyond said G2 phase of the cell cycle by increasing intracellular expression of a cyclin-dependent kinase inhibitor. 26. A method for inducing apoptosis of tumor cells in vivo, comprising the steps of: administering to a living patient a therapeutically active dose of a peptide that inhibits intracellular proteasome function; and administering to the patient a therapeutically active dose of a different substance that inhibits intracellular protein synthesis, said administering steps being carried out in such a manner that the effects thereof are concurrent. 27. A method for inducing apoptosis of tumor cells in vivo, comprising the steps of: administering to a living patient a therapeutically active dose of a peptide that inhibits intracellular proteasome function; and administering to the patient a therapeutically active dose of a different substance that increases intracellular expression of a cyclin-dependent kinase (CDK) inhibitor, said administering steps being carried out in such a manner that the effects thereof are concurrent. 28. The method of claims 26 or 27, wherein the peptide is N-acetyl-leucinyl-leucinyl-norleucinal (LLnL) or N-acetyl- leucinyl-valinyl-phenylalaninal (LVP) , and wherein the different substance is a ribonuclease (RNase) . 29. A method for inducing apoptosis of tumor cells in vivo, comprising the steps of: administering to a living patient a therapeutically active dose of a peptide selected from a group consisting of W-acetyl-leucinyl-leucinyl-norleucinal (LLnL) and N-acetyl - leucinyl-valinyl-phenylalaninal (LVP) ; and administering to the patient a therapeutically active dose of ranpirnase, said administering steps being carried out in such a manner that the effects thereof are concurrent. 30. The method of claim 29, wherein said administering steps are carried out by intravenously injecting ranpirnase and the selected peptide.

Inventors: MIKULSKI STANISLAW M, MIKULSKI, STANISLAW, M.
Applicants: ALFACELL CORP, ALFACELL CORPORATION
Application year: 1999
Main classification: A61K38
IPC codes: A61K38, A61K45, A61P35, C12N5